Financial Report: Lilly

Lilly

4Q Revenues: $5.1 billion (-12%)

4Q Earnings: $428.5 (-41%)

FY Revenues: $19.6 billion (-15%)

FY Earnings: $2.4 billion (-49%)

Comments: Results were impacted by U.S. patent expirations for Cymbalta (-58% to $367 million in 4Q14) and Evista (-74% to $72 million in 4Q14) and the unfavorable impact of foreign exchange rates. Alimta sales were flat at $725 million in the quarter. Humalog sales were $729 million (-1%). Cialis sales were up 6% to $622 million. Humulin sales were $396 million, up 7%. Forteo sales were up 6% to $381 million. Zyprexa sales were down 27% to $253 million. U.S. revenue decreased 19% to $2.5 billion, due to patent expirations. Revenue outside the U.S. decreased 3% to $2.7 billion, primarily due to unfavorable exchange rates. In the quarter, the company recognized acquired in-process R&D charges of $105.2 million associated with revisions to its agreement with Boehringer Ingelheim, and its collaboration with Adocia. On January 1, 2015, the company completed the acquisition of Novartis Animal Health for approximately $5.4 billion in cash.